IPSC Earnings & Financial Statements
Century Therapeutics, Inc.
$1.44
+$0.06(+3.99%)
36
Overall
60
Value
18
Tech
31
Quality
Market Cap
$249.88M
Volume
319.34K
52W Range
$0.44 - $3.04
Target Price
$5.12
IPSC earnings and financial statements: Century Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IPSC Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $109.16M | $6.59M | $2.23M | $5.20M | - |
| Operating income | -$17.27M | -$138.14M | -$146.55M | -$133.83M | -$94.88M |
| EBITDA | $3.43M | -$111.47M | -$121.11M | -$120.90M | -$90.45M |
| Net income | -$9.60M | -$126.57M | -$136.67M | -$130.93M | -$95.82M |
| EPS (diluted) | $-0.14 | $-1.61 | $-2.30 | $-2.27 | $-2.96 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $223.70M | $353.22M | $360.69M | $486.54M | $437.38M |
| Total liabilities | $64.77M | $191.85M | $175.94M | $183.81M | $41.14M |
| Shareholders’ equity | $158.94M | $161.36M | $184.75M | $302.74M | $396.24M |
| Cash and equivalents | $61.85M | $58.44M | $47.32M | $84.27M | $56.45M |
| Long-term debt | $40.24M | $48.96M | $46.66M | $42.44M | $23.46M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$103.90M | -$110.14M | -$88.35M | $14.05M | -$89.00M |
| Capital expenditure | -$848.0K | -$154.0K | -$13.74M | -$30.60M | -$44.97M |
| Free cash flow | -$104.75M | -$110.29M | -$102.08M | -$16.55M | -$133.97M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IPSC | $1.44 | +4.0% | 319.34K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Century Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW